Friday, 30 October 2026
Misconduct referrals hit 12-year high, AI scribe licence dispute, Peptide anaphylaxis prompts inquiry call
- 01
Tribunal referrals for potential misconduct reach 12-year high
AHPRA referred 295 practitioners to tribunals for potential professional misconduct in 2025–26, up 53.6% from the previous year and the highest number since 2013–14. Notifications lodged directly with AHPRA fell 4.7% to 12,698, although combined notifications across AHPRA, the Health Professional Councils Authority and the Office of the Health Ombudsman rose 3% to 23,327. There were 12,994 notifications concerning 9241 medical practitioners across the three bodies, equivalent to 6% of medical practitioners, with almost half relating to clinical care. AHPRA completed a record 13,171 notifications, closed 64% within six months and reduced matters open for at least 12 months by 21.2%. Of closed notifications, 1.2% resulted in a practitioner losing registration or being disqualified from applying for registration.
via RACGP newsGP · also covered by The Medical Republic
- 02
Best Practice says Heidi II use breaches Bp Premier licence
Using Heidi II with Bp Premier constitutes a breach of the software’s End User Licence Agreement, Best Practice told users. The vendor said it had not consented to Heidi II accessing its software or database and requested that customers comply with the licence terms. It is updating the agreement with the Oxford SP2 program update to clarify that bots, scraping tools and robotic process automation are not permitted, citing concerns about clinical information integrity, patient safety, privacy, security and regulatory compliance. Heidi Health rejected aspects of Best Practice’s claims and accused the vendor of restricting interoperability, saying Heidi II has privacy safeguards, clinician supervision and guardrails around its functions. The dispute follows a TGA review that found eight of 12 investigated AI scribes had functions likely to require medical device regulation, although the regulator did not identify which products were flagged.
- 03
Fatal peptide-linked anaphylaxis renews telehealth inquiry call
Victoria’s chief health officer has flagged 13 anaphylaxis cases associated with unapproved peptides since July 2025, including five in September. A Victorian coroner concluded that Richard Norton, 75, died after injecting CJC1295 and Ipamorelin in excess of the dose prescribed by his medical practitioner. The coroner recommended that the TGA review unapproved peptides and consider further restrictions on their use. New state guidance asks health practitioners to notify the Victorian Department of Health of anaphylaxis cases and note any potential peptide link, while the TGA has requested adverse-effect reports. Federal MP Dr Monique Ryan has renewed her call for a parliamentary inquiry into online prescribing and telehealth business models, although the coroner’s report did not mention telehealth.
- 04
More than 1100 doctors gain rural generalist recognition
More than 1100 medical practitioners have gained AHPRA recognition as rural generalists since applications opened to doctors with ACRRM or RACGP rural fellowships on 1 September. Rural generalist will become a protected title on 29 March 2027, after which doctors without subspecialist recognition on their AHPRA registration cannot use it. RACGP rural chair Associate Professor Michael Clements said recognition provided a foundation for negotiations over MBS items, prescribing, MRI rebates, hospital recognition, pay and conditions. A working group has also proposed dedicated MBS item numbers for rural generalists using advanced skills and an extended scope of practice, but the article reported no further progress as of May.
- 05
Holding biologics or JAK inhibitors after COVID boosters increased flares
Withholding biologic or JAK inhibitor therapy for two weeks after a COVID booster did not improve antibody responses and more than doubled the odds of an inflammatory arthritis flare. The US multicentre COVER trial randomised 840 patients with rheumatoid arthritis, psoriatic arthritis or axial spondyloarthritis to interrupt or continue treatment. Antibody levels rose substantially in both groups, while treatment interruption was associated with greater flare odds overall (OR 2.27; 95% CI 1.41–3.65) and particularly among JAK inhibitor users (OR 3.65; 95% CI 1.69–7.87). Increased disease activity appeared transient and was comparable between groups at six weeks, but the researchers concluded that the findings did not support routine temporary interruption to optimise COVID-19 vaccination.
- 06
FDA approves first transcatheter device for paravalvular leaks
The US Food and Drug Administration has approved Abbott’s Amplatzer Paraclose PVL Occluder to close paravalvular leaks around surgical replacement heart valves. The first minimally invasive device approved in the US for this indication, it offers an alternative to repeat open-heart surgery and is implanted via a catheter delivered through a leg artery or vein. Abbott said paravalvular leaks occur in 7% to 17% of mitral valve replacements and 5% to 10% of aortic valve replacements, and can cause shortness of breath, leg and foot swelling, and red blood cell damage. Approval was supported by the prospective, multicentre, single-arm PARADIGM trial involving 200 patients, with 30-day results due to be presented at an upcoming conference.
via MedTech Dive
MDDR is a news digest for medical professionals. It is not medical advice and should not be relied on for clinical decision-making.